CYP2B6 and B-cell chronic lymphocytic leukemia: When considering the aforementioned information along with the higher frequency of (GT) and (TT) genotypes observed in patients with chromosomal aberrations (p < 0.001), one could hypothesize that CYP2B6 enzyme deficiency could influence a person’s susceptibility to heamatotoxic exposure to leukemogens and could raise the risk of developing B-CLL.